Frank Weinberg, MD
Medical Oncology · Ann Arbor, MINPI 1952714032
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $134,734 of the $194,612 with a category attached, or 69.2%. 25 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 45.0% of the total. 2025 is the largest year on record at $93,749, more than ten times the $105 reported in 2020. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $872.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$88K
- Amgen$36K
- Regeneron Healthcare Solutions, Inc.$36K
- AstraZeneca$9K
- Johnson & Johnson$7K
- Eli Lilly$6K
- plus $13K from 19 others
Across 156 payments — averaging $6746.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$545K
- AbbVie$252K
- Regeneron$181K
- Eli Lilly$61K
- Genentech, Inc.$15K
- E.r. Squibb & Sons, L.L.C.$89
What the payments were for
- Consulting fees$48,04825%
- Speaking & faculty fees$134,73469%
- Travel & lodging$3,8062%
- Food & beverage$7,6124%
- Education$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 52 | $87,589 |
| Amgen | 37 | $36,361 |
| Regeneron Healthcare Solutions, Inc. | 52 | $36,308 |
| AstraZeneca | 16 | $8,765 |
| Johnson & Johnson | 10 | $6,801 |
| Eli Lilly | 5 | $6,101 |
| Pharmacosmos Therapeutics Inc. | 4 | $4,297 |
| AbbVie | 4 | $2,946 |
| Regeneron | 3 | $2,177 |
| Sanofi | 1 | $1,140 |
| Lilly USA, LLC | 4 | $357 |
| Boehringer Ingelheim | 5 | $291 |
| Merck | 11 | $258 |
| G1 Therapeutics, Inc. | 4 | $253 |
| AVEO Pharmaceuticals, Inc. | 1 | $238 |
| E.r. Squibb & Sons, L.L.C. | 2 | $136 |
| Pfizer | 1 | $135 |
| Tempus AI, Inc | 3 | $134 |
| Daiichi Sankyo Inc. | 1 | $79 |
| Genentech USA, Inc. | 1 | $68 |
| Bard Peripheral Vascular, Inc. | 1 | $58 |
| EMD Serono, Inc. | 2 | $44 |
| Immunocore Limited | 1 | $30 |
| Novartis | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$194,612 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 49 | $753,571 |
| MekinistTrametinib Dimethyl Sulfoxide | 14 | $199,081 |
| TafinlarDabrafenib Mesylate | 15 | $198,220 |
| Prochlorperazine Maleate | 19 | $352 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $154 |
| Gabapentin | 12 | $130 |
| Olanzapine | 11 | $87 |
| Dexamethasone | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $8,765 | $753,57149 claims |
| NovartisMekinist, Tafinlar | $25 | $397,30129 claims |
| Lilly USA, LLCOlanzapine | $357 | $8711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Ann Arbor
- Harry ErbaAnn Arbor$1.1M
- Francis WordenAnn Arbor$142K
- Maha HussainAnn Arbor$114K
- Moshe TalpazAnn Arbor$83K
- Vaibhav SahaiAnn Arbor$80K
- Howard TerebeloAnn Arbor$47K
- Angel QinAnn Arbor$41K
- Erin CobainAnn Arbor$38K
- Phillip PalmbosAnn Arbor$37K
- Rashmi ChughAnn Arbor$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.